Literature DB >> 15695475

Controlling hyperglycemia as an adjunct to cancer therapy.

Cheryl A Krone1, John T A Ely.   

Abstract

Hyperglycemia is commonly manifested in cancer patients. Although high intakes of sugar and refined carbohydrates and elevated blood glucose are strongly associated with the risk of cancer, much less is known about their effects on survival after cancer diagnosis. There is evidence that high carbohydrate intake is associated with poorer survival after diagnosis for early breast cancer. We measured glycated hemoglobin in a group of cancer patients (some with active disease and some in remission) and found a statistically significant lower average blood glucose in those in remission. Glycated hemoglobin provides an indication of average blood glucose over 2 to 3 months. The authors discuss lifestyle changes including diet and physical activity that can reduce average blood glucose. Ascorbic acid (AA) supplementation as an adjunct to cancer therapy is also considered. Furthermore, they present a biologically plausible explanation for how hyperglycemia can impair the actions of AA and damage immune effectiveness and hinder cancer survival. One mechanism is likely a reduction in intracellular AA; high intracellular levels of AA are necessary for optimal activity of the hexose monophosphate shunt. This metabolic pathway is important for maintaining proper cellular antioxidant status in immune cells including lymphocytes involved in cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695475     DOI: 10.1177/1534735404274167

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  27 in total

Review 1.  Promoting a healthy lifestyle among cancer survivors.

Authors:  Wendy Demark-Wahnefried; Lee W Jones
Journal:  Hematol Oncol Clin North Am       Date:  2008-04       Impact factor: 3.722

2.  Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population.

Authors:  Roger C Zhu; Kirk Rattanakorn; Steven Pham; Divya Mallam; Thomas McIntyre; Moro O Salifu; Irini Youssef; Samy I McFarlane; Shivakumar Vignesh
Journal:  Colorectal Cancer       Date:  2017-06-21

3.  Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer.

Authors:  Tianyuan Xu; Zhaowei Zhu; Xianjin Wang; Leilei Xia; Xiaohua Zhang; Shan Zhong; Fukang Sun; Yu Zhu; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2015-05-26       Impact factor: 2.370

4.  Prognostic Significance of Hyperglycemia in Patients with Brain Tumors: a Meta-Analysis.

Authors:  Hongwei Liu; Zhixiong Liu; Bing Jiang; Xiping Ding; Lei Huo; Xin Wan; Jinfang Liu; Zhenyun Xia
Journal:  Mol Neurobiol       Date:  2015-02-17       Impact factor: 5.590

Review 5.  Genetic analysis of the Warburg effect in yeast.

Authors:  Bola Olayanju; James Jensen Hampsey; Michael Hampsey
Journal:  Adv Biol Regul       Date:  2014-09-30

6.  High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells.

Authors:  Han Liu; Qingyong Ma; Junhui Li
Journal:  Mol Cell Biochem       Date:  2010-10-20       Impact factor: 3.396

7.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

Review 8.  Insulin, insulin receptors, and cancer.

Authors:  R Vigneri; I D Goldfine; L Frittitta
Journal:  J Endocrinol Invest       Date:  2016-07-01       Impact factor: 4.256

9.  Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study.

Authors:  Paolo Contiero; Franco Berrino; Giovanna Tagliabue; Antonio Mastroianni; Maria Gaetana Di Mauro; Sabrina Fabiano; Monica Annulli; Paola Muti
Journal:  Breast Cancer Res Treat       Date:  2013-04-09       Impact factor: 4.872

10.  Glucose as a prognostic factor in ovarian carcinoma.

Authors:  Donald M Lamkin; Douglas R Spitz; Mian M K Shahzad; Bridget Zimmerman; Daniel J Lenihan; Koen Degeest; David M Lubaroff; Eileen H Shinn; Anil K Sood; Susan K Lutgendorf
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.